Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Report

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report By Drug Class (MAPK Inhibitors, Tyrosine Kinase Inhibitors, Autotaxin Inhibitors), By Region, And Segment Forecasts, 2019 - 2026

  • Report ID: GVR-3-68038-119-1
  • Number of Pages: 70
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2017
  • Industry: Healthcare

Table of Contents

Chapter 1 Methodology And Scope
                 1.1 Market Segmentation
                 1.2 Market Definition
                 1.3 Information Procurement
                     1.3.1 Purchased Database
                     1.3.2 Gvr’s Internal Database
                     1.3.3 Secondary Sources
                     1.3.4 Primary Research
                 1.4 Information Analysis
                     1.4.1 Data Analysis Models
                 1.5 Market Formulation & Data Visualization
                 1.6 Validation & Publishing
                 1.7 Geographic Scope & Assumptions
                 1.8 Region-Wise Market Calculation
                     1.8.1 Region-Wise Market: Base Estimates
                 1.9 Market Cagr Calculation
                     1.9.1 Region Based Segment Share Calculation
Chapter 2 Executive Summary
                 2.1 Ipf Treatment Market Outlook
                 2.2 Ipf Treatment Market: - Segment Outlook
                 2.3 Ipf Treatment Market: -Competitive Insights
                 2.4 Market Summary
Chapter 3 Market Variables, Trends & Scope
                 3.1 Market Lineage Outlook
                     3.1.1 Parent Market Outlook
                 3.2 Penetration And Growth Prospect Mapping
Chapter 4 Market Dynamics
                 4.1 Market Driver Analysis
                     4.1.1 Growing Geriatric Population Base
                     4.1.2 Growing Prevalence Of Ipf
                     4.1.3 Introduction Of Noverl Drugs
                     4.1.4 Surge In Cigarette Smoking Population
                 4.2 Market Restraint Analysis
                     4.2.1 Unavailability Of The Proper Treatment Options
Chapter 5 Ipf Treatment Market Analysis Tools
                 5.1 Industry Analysis - Porter’s
                     5.1.1 Supplier Power: Low Due To Less Number Of Manufacturers
                     5.1.2 Buyer Power: Moderate Due To Presence Of Players Entering Into Long-Term Contract
                     5.1.3 Substitution Threat: Low Due To No/ Less External Substitutes
                     5.1.4 Threat From New Entrant: Moderate Due To Brand Recognition Of The Existing Players
                     5.1.5 Competitive Rivalry: Moderate Due To Increasing Mergers & Acquisitions By Major Players
                 5.2 Pestel Analysis
                     5.2.1 Political Landscape
                     5.2.2 Environmental Landscape
                     5.2.3 Social Landscape
                     5.2.4 Technology Landscape
                     5.2.5 Legal Landscape
                 5.3 Major Deals & Strategic Alliances Analysis
                     5.3.1 Joint Ventures
                     5.3.2 Mergers & Acquisitions
                     5.3.3 Licensing & Partnership
                     5.3.4 Technology Collaborations
                     5.3.5 Strategic Divestments
Chapter 6 Ipf Treatment Market - Competitive Analysis
                 6.1 Recent Developments & Impact Analysis, By Key Market Participants
                 6.2 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
                 6.3 Public Companies
                     6.3.1 Company Market Position Analysis (Revenue, Geographic Presence, Product Portfolio, Key Serviceable Industries, Key Alliances)
                     6.3.2 Company Market Share/Ranking, By Region
                     6.3.3 Competitive Dashboard Analysis
                     6.3.4 Market Differentiators
                     6.3.5 Synergy Analysis: Major Deals & Strategic Alliances
                 6.4 Private Companies
                     6.4.1 List Of Key Emerging Companies
                     6.4.2 Regional Network Map
                     6.4.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Key Alliance, Industry Experience)
Chapter 7 Drug Class Business Analysis
                 7.1. Definitions & Scope
                 7.2. Drug Class Market Share Analysis, 2018 & 2026
                 7.3. Ipf Treatment Market, By Drug Class, 2014 To 2026
                 7.4. Market Size & Forecasts And Trend Analyses, 2014 To 2026 For The Following,
                 7.5 Mapk Inhibitors
                     7.5.1 Mapk Inhibitors Market, 2014 - 2026 (USD Million)
                 7.6 Tyrosine Kinase Inhibitors
                     7.6.1 Tyrosine Kinase Inhibitors Market, 2014 - 2026 (USD Million)
                 7.7 Autotaxin Inhibitors
                     7.7.1 Autotaxin Inhibitors Market, 2014 - 2026 (USD Million)
Chapter 8 Ipf Treatment Market: Regional Estimates & Trend Analysis
                 8.1. Definitions & Scope
                 8.2. Region Market Share Analysis, 2018 & 2026
                 8.3. Ipf Treatment Market, By Region, 2014 To 2026
                 8.4. Market Size & Forecasts And Trend Analyses, 2014 To 2026 For The Following,
                 8.5 North America.
                     8.5.1 North America Market Estimates And Forecast, 2014 - 2026
                     8.5.2 U.S.
                         8.5.2.1 U.S. Market Estimates And Forecast, 2014 - 2026
                     8.5.3 Canada
                         8.5.3.1 Canada Market Estimates And Forecast, 2014 - 2026
                 8.6 Europe
                     8.6.1 Europe Market Estimates And Forecast, 2014 - 2026
                     8.6.2 Germany
                         8.6.2.1 Germany Market Estimates And Forecast, 2014 - 2026
                     8.6.3 U.K.
                         8.6.3.1 U.K. Market Estimates And Forecast, 2014 - 2026
                     8.6.4 Spain
                         8.6.4.1 Spain Market Estimates And Forecast, 2014 - 2026
                     8.6.5 France
                         8.6.5.1 France Market Estimates And Forecast, 2014 - 2026
                     8.6.6 Italy
                         8.6.6.1 Italy Market Estimates And Forecast, 2014 - 2026
                 8.7 Asia-Pacific
                     8.7.1 Asia-Pacific Market Estimates And Forecast, 2014 - 2026
                     8.7.2 Japan
                         8.7.2.1 Japan Market Estimates And Forecast, 2014 - 2026
                     8.7.3 China
                         8.7.3.1 China Market Estimates And Forecast, 2014 - 2026
                 8.8 Latin America
                     8.8.1 Latin America Market Estimates And Forecast, 2014 - 2026
                     8.8.2 Brazil
                         8.8.2.1 Brazil Market Estimates And Forecast, 2014 - 2026
                     8.8.3 Argentina
                         8.8.3.1 Argentina Market Estimates And Forecast, 2014 - 2026
                 8.9 Middle East And Africa
                     8.8.1 Middle-East And Africa Market Estimates And Forecast, 2014 - 2026
                     8.8.2 South Africa
                         8.8.2.1 South Africa Market Estimates And Forecast, 2014 - 2026
                 8.10.Swot Analysis, By Factor (Political & Legal, Economic And Technological)
                     8.10.1. North America
                     8.10.2. Europe
                     8.10.3. Asia Pacific
                     8.10.4. Latin America
                     8.10.5. Middle East & Africa
Chapter 9 Competitive Landscape
                 9.1 Company Profiles
                     9.1.1 F. HOFFMAN LA ROCHE,
                         9.1.1.1 Company overview
                         9.1.1.2 Financial performance
                         9.1.1.3 Product benchmarking
                         9.1.1.4 Strategic initiatives
                     9.1.2 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                         9.1.2.1 Company overview
                         9.1.2.2 Financial performance
                         9.1.2.3 Product benchmarking
                         9.1.2.4 Strategic initiatives
                     9.1.3 BRISTOL-MYERS SQUIBB COMPANY
                         9.1.3.1 Company overview
                         9.1.3.2 Financial performance
                         9.1.3.3 Product benchmarking
                         9.1.3.4 Strategic initiatives
                     9.1.4 MEDICINOVA, INC,
                         9.1.4.1 Company overview
                         9.1.4.2 Financial performance
                         9.1.4.3 Product benchmarking
                         9.1.4.4 Strategic initiatives
                     9.1.5 MERCK & CO., INC.
                         9.1.5.1 Company overview
                         9.1.5.2 Financial performance
                         9.1.5.3 Product benchmarking
                         9.1.5.4 Strategic initiatives
                     9.1.6 PROMETIC LIFE SCIENCES INC.
                         9.1.6.1 Company overview
                         9.1.6.2 Financial overview
                         9.1.6.3 Product benchmarking
                         9.1.6.4 Strategic initiatives
                     9.1.7 GALAPAGOS
                         9.1.7.1 Company overview
                         9.1.7.2 Financial overview
                         9.1.7.3 Product benchmarking
                         9.1.7.4 Strategic initiatives
                     9.1.8 NOVARTIS AG
                         9.1.8.1 Company overview
                         9.1.8.2 Financial overview
                         9.1.8.3 Product benchmarking
                         9.1.8.4 Strategic initiatives
                     9.1.9 FIBROGEN, INC.
                         9.1.9.1 Company overview
                         9.1.9.2 Financial overview
                         9.1.9.3 Product benchmarking
                         9.1.9.4 Strategic initiatives


List of Tables

TABLE 1 List of abbreviation
TABLE 2 North America IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 3 U.S. IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 4 Canada IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 5 Europe IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 6 Germany IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 7 U.K. IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 8 France IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 9 Italy IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 10 Spain IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 11 Asia Pacific IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 12 Japan IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 13 China IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 14 Latin America IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 15 Brazil IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 16 Argentina IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 17 MEA IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)
TABLE 18 South Africa IPF treatment market estimates and forecasts, by drug class, 2014 - 2026 (USD Million)


List of Figures

FIG. 1 IPF treatment Market Segmentation
FIG. 2 Information Procurement
FIG. 3 QFD modelling for market share assessment
FIG. 4 IPF treatment Market, 2018
FIG. 5 Penetration and growth prospect mapping
FIG. 6 IPF treatment Market Driver Impact
FIG. 7 IPF treatment Market Restraint Impact
FIG. 8 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
FIG. 9 Porter’s Five Forces Analysis
FIG. 10 IPF treatment market: Drug class outlook and key takeaways
FIG. 11 IPF treatment market: Regional movement analysis
FIG. 12 North America
FIG. 13 North America market estimates and forecast, 2014 - 2026
FIG. 14 U.S. market estimates and forecast, 2014 - 2026
FIG. 15 Canada market estimates and forecast, 2014 - 2026
FIG. 16 Europe
FIG. 17 Europe market estimates and forecast, 2014 - 2026
FIG. 18 Germany market estimates and forecast, 2014 - 2026
FIG. 19 U.K. market estimates and forecast, 2014 - 2026
FIG. 20 Spain market estimates and forecast, 2014 - 2026
FIG. 21 France market estimates and forecast, 2014 - 2026
FIG. 22 Italy market estimates and forecast, 2014 - 2026
FIG. 23 Asia Pacific
FIG. 24 Asia-Pacific market estimates and forecast, 2014 - 2026
FIG. 25 Japan market estimates and forecast, 2014 - 2026
FIG. 26 China. market estimates and forecast, 2014 - 2026
FIG. 27 Latin America
FIG. 28 Latin America market estimates and forecast, 2014 - 2026
FIG. 29 Brazil market estimates and forecast, 2014 - 2026
FIG. 30 Argentina market estimates and forecast, 2014 - 2026
FIG. 31 Middle East & Africa
FIG. 32 MEA market estimates and forecast, 2014 - 2026
FIG. 33 South Africa market estimates and forecast, 2014 - 2026
FIG. 34 Strategic framework

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon